Evaluating the Commercial & Pharmaceutical Viability of Radioisotopes to Benchmark Potential
Time: 9:00 am
day: Pre-Conference Workshop Day
Details:
This workshop will focus on assessing the commercial and pharmaceutical viability of new isotopes in radiopharmaceutical production. Participants will explore the challenges and strategies for bringing isotopes actinium-225, lutetium-177, lead-212 and copper-67 to market.
This workshop will cover:
- Assessing Market Demand and Commercial Viability: Examine the market demand for new isotopes by analyzing therapeutic potential, competitive landscape, and pricing strategies. Discuss the projected market size, patient demographics, and revenue opportunities for isotopes like copper-67, actinium-225, and lutetium-177.
- Navigating Radiopharmaceutical Development Challenges: Explore the pharmaceutical challenges in developing new isotopes and radiopharmaceuticals, including production scalability, quality control, and regulatory compliance. Discuss the technical and logistical hurdles in bringing these radiopharmaceuticals from research to clinical application, ensuring they meet GMP standards.
- Strategic Partnerships and Investment Opportunities: Identify key strategic partnerships and investment opportunities that can support the development and commercialization of new isotopes. Discuss the role of venture capital, corporate investments, and licensing agreements in overcoming financial and operational barriers.
